Dihexa vs Davunetide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin IV, engineered at Washington State University to be orally active and to cross into the brain. The pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. The reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and in April 2025 the journal retracted two of the key papers behind its proposed mechanism (2012 and 2014) after a university investigation.
Also: NAP, AL-108
Davunetide (NAP) is an eight-amino-acid fragment (NAPVSIPQ) of activity-dependent neuroprotective protein (ADNP), discovered at Tel Aviv University and given as a nasal spray. It was meant to protect brain cells by stabilizing microtubules, the scaffolding that tau normally supports. Its big test, a phase 2/3 trial in progressive supranuclear palsy (PSP), failed cleanly in 2012, and development stalled. It has since been revived by its inventors, who argue it works in women and are pursuing ADNP syndrome, but those claims rest on reanalyses of old data, not a new successful trial.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Davunetide has stronger research evidence (Human Trials) compared to Dihexa (Animal Studies).
Detailed Comparison
| Attribute | Dihexa | Davunetide |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dihexa is derived from angiotensin IV, a fragment of the renin-angiotensin system that has long been linked to memory in animal work. The leading hypothesis is that it acts on the hepatocyte growth factor (HGF) and its receptor c-Met, a growth-factor system that drives the formation of new dendritic spines and synapses. In cultured hippocampal neurons, dihexa and related angiotensin IV analogs increase spine density, and that effect disappears when the HGF/c-Met system is blocked, which is the main evidence the pathway matters. It is worth being blunt that the exact molecular interaction has been contested, since the original paper proposing direct HGF binding was retracted, so the mechanism is best treated as a working hypothesis rather than settled fact. | NAP comes from ADNP, a protein essential for brain development. In cell and animal studies it interacts with microtubule end-binding proteins (EB1 and EB3), promoting microtubule stability and reducing tau phosphorylation, which is why it was aimed at tauopathies like PSP and Alzheimer's disease. Mutations in the ADNP gene itself cause ADNP syndrome (Helsmoortel-Van der Aa syndrome), and in ADNP-deficient mice NAP improved some behavioral and neural measures, the rationale for that newer program. The PSP trial did not include target-engagement measures, so it never showed the drug was actually doing this in human brains. |
| Common Dosing | 5-20 mg daily Once daily | 30 mg intranasal twice daily (PSP trial dose) Once or twice daily |
| Administration | Oral, sublingual, or intranasal | Intranasal spray (an IV form, AL-208, was tested in cardiac surgery) |
| Typical Duration | Cycles of 2-4 weeks | 12 weeks to 52 weeks in trials |
| Best Time to Take | Morning | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The published evidence on dihexa is entirely preclinical. Harding, McCoy and colleagues at Washington State University reported that metabolically stabilized angiotensin IV analogs, including dihexa, restored cognition in scopolamine-impaired and aged rats (J Pharmacol Exp Ther, 2013; this paper carries a 2021 expression of concern but is not retracted). A 2014 JPET study tied the procognitive and synaptogenic effects to the HGF/c-Met system, but that paper was retracted in April 2025, together with the 2012 paper that first proposed dihexa as an HGF/Met modifier, after the journal had flagged them with expressions of concern in 2021. There are no registered human clinical trials and no published human safety or pharmacokinetic data, so dosing, long-term safety and whether any of the rodent benefit translates to people are all unknown. The often repeated 'millions of times more potent than BDNF' line comes from a single cell assay and should not be read as a clinical fact. Treat dihexa as a research molecule with interesting but shaken animal data, not as a proven cognitive enhancer. | The headline result is negative. In the phase 2/3 PSP trial (Boxer and colleagues, Lancet Neurology 2014), 313 patients got 30 mg intranasal davunetide twice daily or placebo for 52 weeks. Disease progression was identical in both groups on both primary measures (PSP Rating Scale and Schwab and England daily living scale), and the authors concluded davunetide is not an effective treatment for PSP. Earlier phase 2 work was mixed: a 12-week trial in 144 people with amnestic mild cognitive impairment hinted at working-memory benefits, and a schizophrenia trial missed one co-primary endpoint while hitting another. The original developer, Allon Therapeutics, stopped investing and was later absorbed by Paladin Labs. The revival comes from the inventor's group: post hoc reanalyses of the PSP data (Translational Psychiatry 2023, Molecular Psychiatry 2026) report that women declined faster than men and that davunetide slowed decline in women only. A similar sex-split reanalysis of the MCI trial was published in 2024. These findings are interesting but are subgroup analyses of trials that failed overall, done by researchers tied to the company now developing the drug (ExoNavis Therapeutics), so they need a new prospective trial to mean much. ExoNavis has said a phase 3 in children with ADNP syndrome began in 2024, but Alzforum could not find it in trial registries. Davunetide holds FDA orphan and rare pediatric disease designations and EMA orphan status for ADNP syndrome. |
Frequently Asked Questions: Dihexa vs Davunetide
What is the difference between Dihexa and Davunetide?
Dihexa is a cognitive peptide that dihexa (n-hexanoic-tyr-ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin iv, engineered at washington state university to be orally active and to cross into the brain. the pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. the reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and in april 2025 the journal retracted two of the key papers behind its proposed mechanism (2012 and 2014) after a university investigation. Davunetide is a cognitive peptide that davunetide (nap) is an eight-amino-acid fragment (napvsipq) of activity-dependent neuroprotective protein (adnp), discovered at tel aviv university and given as a nasal spray. it was meant to protect brain cells by stabilizing microtubules, the scaffolding that tau normally supports. its big test, a phase 2/3 trial in progressive supranuclear palsy (psp), failed cleanly in 2012, and development stalled. it has since been revived by its inventors, who argue it works in women and are pursuing adnp syndrome, but those claims rest on reanalyses of old data, not a new successful trial. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dihexa or Davunetide?
Neither is universally "better" - the choice depends on your specific goals. Dihexa is typically used for cognitive purposes, while Davunetide is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dihexa and Davunetide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dihexa and Davunetide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.